Expectations trend
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsNASDAQConsumer StaplesFood DistributionSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MTEX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Cash flow from operations stays positive | Cash flow from operations turned positive at $1.1M in 2026-Q1. | Intact | cash flow turns negative again next year | Cash from operations: $-792,000 FY2026-Q2; GAAP. Published target: >0 USD. Target period is not explicitly aligned with this observation. Aug 12, 2026-792,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making business in a sector with a current tailwind, though MTEX returned to positive operating income and net income in 2026-Q2. Its multi-year view remains on watch: recent signals improved from mixed to mildly favorable, but performance still sits below its industry cohort.
The valuation evidence points to MTEX being cheap versus peers, with a negative expectations gap, but confidence in that reading is low. The snapshot labels what is priced in as justified and fragility as low, so the evidence does not point to concentrated fragility in current expectations.
Near term, profitability has improved: 2026-Q2 operating income and net income were positive, and sales grew 5.1% in constant dollars from a year earlier. Cash flow also improved, but annual 2025 operating cash flow was negative, recent quarters have included earnings misses, and the next-quarter miss risk is elevated. Recent accountant changes and litigation add uncertainty.
Over the next few quarters, the key test is whether MTEX can sustain higher revenue, operating income, and cash flow. A weakening jobs trend could increase recession concerns for cyclical names, while continued strong results from sector bellwethers SYY, USFD, and PFGC could support the sector backdrop. Misses or lower guidance from those companies could weaken that tailwind.
The 1-3 year thesis is a watch case, not a settled recovery: recent operating progress is encouraging, but earnings reliability, cash generation, legal developments, and the sector backdrop remain important uncertainties. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A new CFO may help fix financial problems. |
| Under Pressure |
| financial results worsen after CFO transition |
Nasdaq equity <$2.5M vs >=$2.5M Nasdaq notified MTEX of non-compliance with $2.5M equity requirement; BDO dismissed as auditor. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating income improves to positive levels | A primary condition in Mannatech Inc's published investment case. The stated target is >0 USD. | Broken | operating income remains negative over next 4 quarters | Operating income: $998,000 FY2026-Q2; GAAP. Published target: >0 USD. Target period is not explicitly aligned with this observation. Aug 12, 2026998,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Quarterly revenue holds near $25M | Management focuses on keeping revenue near $25M quarterly. | Intact | revenue falls below $24.9M consistently next year | Revenue: $26.65M FY2026-Q2; GAAP. Published target: >=24.9M USD. Target period is not explicitly aligned with this observation. Aug 12, 202626,650,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.